openPR Logo
Press release

Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years | Key Players are Mallinckrodt Pharmaceuticals, Pharmalink AB, Anthera Pharmaceuticals, Rigel Pharmaceuticals Inc., Retrophin, Omeros

03-27-2019 02:08 PM CET | Health & Medicine

Press release from: Pharma Proff

Immunoglobulin A (IgA) Nephropathy to Witness an Exponential

According to a new research report “Immunoglobulin A (IgA) Nephropathy-Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2028” published by Pharma Proff, Immunoglobulin A (IgA) Nephropathy therapeutics currently exhibits a proliferating pipeline with 24 therapeutic candidates.

Download the sample report @ https://www.pharmaproff.com/request-sample/1211

IgA Nephropathy is referred to being as the utmost causing agent of Glomerulonephritis, which is the inflammation of the glomeruli (part of the kidney that filters blood). IgA antibodies are produced by immune system and act as first line of defense against inhaled and ingested pathogens. IgA Nephropathy is an auto immune disorder caused due to the accumulation of the immunoglobulin A (IgA) which results in inflammation and further damages the glomeruli in kidney. This damage to kidney results in presence of blood and protein in urine, and over time may progress to end-stage renal disease (ESRD).

Get the detailed analysis @ https://www.pharmaproff.com/report/iga-nephropathy-pipeline-analysis

According to research findings, majority of the drug candidates in IgA Nephropathy pipeline are undergoing Phase II trials and have shown positive results. It has been observed that subcutaneous route of administration is convenient because of more efficacy and safety; it is more adoptable because of its larger dosage, that can be transmitted subcutaneously; sustainable release of drugs is possible as the muscles can slowly release the drugs into the body. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1211

The epidemiology analysis in the report provides risk factors and trends of IgA Nephropathy in seven major markets (7MM, including U.S., Japan, and EU5 [which includes Germany, France, U.K., Italy, and Spain]) and gives a ten-year forecast for the prevalent and treated cases of IgA nephropathy in each of the regions in pediatric, adult, and geriatric populations. Europe is likely to have the highest number of prevalent cases of IgA Nephropathy among the 7MM throughout the period of analysis.

Some of the key players involved in the development of the drug candidates for IgA Nephropathy in the late and mid stage include Mallinckrodt plc, Calliditas Therapeutics AB., Anthera Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Merck KGaA, Retrophin Inc., and Omeros Corporation.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years | Key Players are Mallinckrodt Pharmaceuticals, Pharmalink AB, Anthera Pharmaceuticals, Rigel Pharmaceuticals Inc., Retrophin, Omeros here

News-ID: 1674880 • Views:

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developments
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant Growth due to Increasing Strategic Developments in the Coming Years | Top Players are Orphazyme A/S, IntraBio Ltd., CTD Holdings, Inc., Mallinckrodt Pharmaceuticals, SOM Biotec
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for IgA

Europe IgA Nephropathy Market Growing at a Tremendous CAGR of 19.2% by 2028
Europe IgA Nephropathy market research report, principal attributes such as highest level of spirit, practical solutions, dedicated research and analysis, innovation, talent solutions, integrated approaches, most advanced technology and commitment plays a key role. All of these features are strictly applied while building this market report for a client. It presents a definite solution to obtain market insights with which businesses can think about market place clearly and thereby take
IgA Antibody Market Significantly Stepping towards the Success Till 2027|Novarti …
The global IgA Antibody market size is projected to reach US$ 5.2 Billion by 2027, at a CAGR of 5.7% during 2021-2027. The central points that fuel the market development during the gauge time frame remember increment for geriatric populace and number of hemophilic patients, further developed immunoglobulin creation attributable to the rise of trend setting innovations, and upgraded cleaning methods. Besides, flood in pervasiveness infections, for example, ongoing provocative
IgA Nephropathy Therapeutics Analysis by Key Players Mallinckrodt Pharmaceutical …
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the period 2016 – 2025. Browse report sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample *Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline Various new technologies are being used by the companies for the development of drugs to treat IgA nephropathy. For instance, TARGIT drug
North America has been the Largest Global Identity Governance and Administration …
Global IGA market is on the rise due to increasing demand from enterprises to identify their users, control whatever they can access, and further audit their activities for security of information. Apart from this, since IGA also provides businesses with numerous supplementary functions, including auditing and policy management, its adoption by business leaders across industries, is expected to escalate in near future. The global IGA market is segmented on the
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
IgA Nephropathy Exhibits Emerging Pipeline with 11+ Drug Candidates
The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage and three drug candidates are in Pre-Clinical stage. Also, there are two inactive drug candidates and one discontinued drug candidate. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in